Treatment of Duchenne muscular dystrophy using bone marrow and cord blood mesenchymal stem cell transplantation
杨晓风,许忆峰,张轶斌,王红梅,吕乃武,吴雁翔,吕欣,崔激萍,单鸿,周金旭,Yang Xiao-feng,Xu Yi-feng,Zhang Yi-bin,Wang Hong-mei,Lü Nai-wu,Wu Yan-xiang,Lü Xin,Cui Ji-ping,Shan Hong,Zhou Jin-xu
DOI: https://doi.org/10.3969/j.issn.1673.8225.2009.36.002
2009-01-01
Abstract:BACKGROUND: Duchenne muscular dystrophy (DMD) is a cureless disease, it is a severe result of progressive atrophy of muscle cells, which caused by various defects. Recently, study concerning ameliorating neuromuscular disorders using stem cells has gained attention. OBJECTIVE: The scheme of combining autologus bone marrow mesenchymal stem cells (BMSCs) and cord blood mesenchymal stem cells (CMSCs) transplantation was first used here to treat DMD by intravenous or local injection. This study was aimed to investigate its safety and feasibility. DESIGN, TIME AND SETTING: A self-control study. PARTICIPANTS: Totally 31 DMD cases were treated by the scheme of combining BMSCs and CMSCs transplantation at Cell Treatment Center, 463 Hospital of Chinese PLA, from June 2007 to September 2008, were selected, including 29 males, and 2 females (twins), mean aged 9.7 years, mean course of 5.1 years, and 11 cases had a positive family history. All the cases were final diagnosed by clinical manifestations, enzymology, electromyogram, MRI and pathological of biopsy muscle specimen. METHODS: Autologous bone marrow was collected from patients, and puncture was done from double ilium, about 80-150 mL bone marrow from each case, separated by Ficoli, then differentiated into cell suspension with density of 1×10 10/L. (1.5-6.0)×108 stem cells were injected into limbs of cases with multipoint method. In addition, 80-145 mL cord blood from healthy parturient were prepared for CMSCs, which intravenous injected into patients with number of (1.0-4.8)×106, once per week, for 3 successive weeks. MAIN OUTCOME MEASURES: Activities of daily living (ADL), clinical grading, enzymology, electromyogram, and MRI changes. RESULTS: All cases were followed up 15 months, without loss. Compared to before transplantation, the motor function was improved with increased ADL scores in 26 cases (84.7%) at months 3, 6, 9, 12, and 15 after transplantation (P < 0.05). In addition, the levels of creatine kinase, and lactate dehydrogenase decreased in 11 cases, increased in 8 cases at 6 months after transplantation. Electromyogram and MRI were checked in 5 cases, 2 patients improved slightly after 6 months. The results showed that 12 cases (38.7%) of 31 patients obtained marked effect, 14 cases (45.2%) were effective and 5 cases (16.1%) were no changed. Total effective rate was 83.9%. There was no adverse reaction in course of treatment. CONCLUSION: BMSCs and CMSCs transplantation can ameliorate clinical manifestations of 83.9% DMD cases, which show the ability to contribute to muscle repair, improvement of blood supply and long term reconstitution of dystrophy muscle. This is a new method for DMD treatment without reject reaction.